Dermatology Innovation Forum 2024

Biography

Anthony has an extensive background with nearly 30 years of experience in academic research, focusing on advanced technology and instrumentation development. In addition to his role as CEO and Co-founder of Wearifi Inc he is currently serving as the Director of Engineering Research at the Querrey Simpson Institute for Bioelectronics (QSIB) at Northwestern University in Chicago IL, managing large groups of postdocs, research associates, and graduate students. These teams tackle a broad range of multidisciplinary topics including new classes of device technologies; medical, flexible electronics, biomimetic, photovoltaics, microfluidics, and micro-electromechanical systems. In addition to his academic achievements, Anthony has made significant contributions in transferring academic innovations to the corporate world. Through successful collaborations with prominent companies such as Loreal, Medtronic, GE, Drager, Gatorade, Reebok, MC10, Semprius, and CoolEdge Lighting, he has played a pivotal role in driving the scalable commercialization of products. Anthony has demonstrated the ability to bridge the gap between academia and industry, ensuring that cutting-edge research can be effectively applied to real-world solutions.

Biography

Frederick C. Beddingfield III is a physician-scientist and biotech entrepreneur. He is currently an Executive Partner at Apollo Health Ventures. Previously Frederick was the CEO and member of the board of directors of Kira Pharmaceuticals, a development stage complement therapeutics biotech company focused on immunology, inflammation, and rare diseases. He was founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. and took the company public in 2017. Prior to Sienna, Frederick served as Chief Medical Officer of Kythera Biopharmaceuticals from March 2013 until it was acquired by Allergan in 2015. Frederick worked at Allergan for 10 years (2003-2013) where he served in various roles including the Therapeutic Area Head of Dermatology and Chief Medical Officer Allergan Medical. He has led the development and approvals of global leading brands in medical dermatology, aesthetics, neurology, metabolic, and other therapeutic areas. These brands include Botox (cosmetic, hyperhidrosis, spasticity, and other), Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac. Frederick has led four successful FDA advisor committees.

Since completing his training, Frederick has maintained a clinical and teaching practice at UCLA. He is a board-certified dermatologist and emergency medicine physician and fellowship trained in dermatologic surgery and cutaneous oncology. Frederick completed his medical degree with honors at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the board of directors of Cytrellis Biosystems, Inc. and on the medical advisory board of the Children’s Skin Disease Foundation and Camp Wonder. He is on the board and co-founder of the Dermatology Summit and Dermatology Innovation Forum conferences, part of Advancing Innovation in Dermatology, a non-profit organization.

Biography

I am a physician scientist who runs an immunogenetics lab at Northwestern University in Chicago, Illinois. We utilize high dimensional multiomic data to identify the molecular and cellular drivers of T cell diseases, T cell neoplasms, skin cancer, and more recently autoimmune disease. We then utilize forward genetic screens to identify novel therapies for these diseases. For example, we have utilized bulk and single cell DNA and RNA Seq to identify the cellular and molecular bases of cutaneous CD4+, CD8+, CD4-CD8-, gd, and B cell lymphomas. We have found that these lymphomas retain the immunological properties of their cell of origin, leading to clinically relevant propensity to skin inflammation, cytokine-driven paraneoplastic syndromes, and metastatic spread to visceral organs. Collectively, these studies have identified novel biomarkers and novel therapeutic approaches, which are currently in clinical trials. This work has been published in Nature, Nature Cancer, Blood, Nature Communications, and Cell Reports. Our lab has been supported by the NIH Director’s Fund, the Damon Runyon Cancer Foundation, the Doris Duke Foundation, and the Mark Foundation. Lastly, our work has led to intellectual property that is the foundation for a new company, Moonlight Bio, that is designing next-generation T cell therapies for cancer.

Biography

Doris Day, MD, is a board-certified dermatologist who specializes in cosmetic and dermatology on the Upper East Side in New York City. She is a clinical associate professor of dermatology at the New York University Medical Center where she was presented with the award for Dedication and Excellence in the Teaching of Dermatology. She has also won the American Skin Association award for mentorship in dermatology and the AAD Presidential Citation in recognition of her dedication and leadership in the field of aesthetic dermatology. She was most recently named by Newsweek as the #3 top cosmetic dermatologist in the US.

She has won awards for her work in laser research and continues to actively participate in FDA clinical research trials and publish in peer reviewed medical journals. Dr. Day regularly lectures nationally and internationally to her peers and the public. She is an active member of many organizations including the American Society of Dermatologic Surgery, the American Academy of Dermatology and the Women’s Dermatologic Society.

Dr. Day also has a master’s degree in medical journalism and is host of the Dermatology Show on Doctor Radio on Sirius/XM 110 for over 15 years and has frequent appearances on many national media outlets and podcasts. She is the author of four books, her most recent book is Rebooting the Biome.

Biography

Dr. Ellebrecht received his MD from the University of Lübeck, Germany. He subsequently completed a research fellowship in the Payne lab, where he invented the chimeric autoantibody receptor (CAAR) T cell concept and advanced several additional cellular immunotherapy technologies that have been licensed to industry partners. He completed his dermatologic residency at the University of Pennsylvania’s 2+2 Physician Scientist track and is an Assistant Professor in the Department of Dermatology and the Center for Cellular Immunotherapies at the University of Pennsylvania. The combined focus of the Ellebrecht lab is to understand immune cells in the context of autoimmunity and manipulate them for use as precision cellular immunotherapies.

Biography

Dr. Lilit Garibyan is a board-certified, practicing dermatologist and Associate Professor of dermatology at Harvard Medical School and Physician-Scientist at Wellman Center for Photomedicine at Massachusetts General Hospital. She has expertise in cutting edge translational research in areas of device development, dermatology, cutaneous neurobiology, adipose tissue, and immunology. She has spent 20+ years at Harvard Medical School, where she has taught and trained students, residents and fellows in dermatology, laser and energy-based devices, and problem-based innovation. Her research focuses on innovative biomedical translational discoveries aimed at identifying unmet medical needs and working with multidisciplinary teams to develop novel treatments for those needs. Dr. Garibyan is an inventor on >16 pending and granted patents, has published over 58 original, peer-reviewed publications and has obtained over $5.3 million grant funding from Department of Defense and NIH for her innovative research. She is the inventor of a platform cooling technology with various therapeutic applications that has led to three venture-backed, start-up companies. She is the scientific co-founder of two of those companies.

Dr. Garibyan is the co-founder and the Director of the “Magic Wand Initiative” and the “Virtual Magic Wand” programs, which teach the process of innovation to clinicians. These internationally-recognized programs empower, engage, and teach healthcare professionals on how to identify unmet needs and collaborate to identify and implement solutions to problems. Dr Garibyan has given many national and international lectures on the topic of engaging clinicians in problem-based innovation. She had directed sessions and led workshops in national and international meetings designed to engage healthcare workers in innovation.

Dr. Garibyan received her B.S. summa cum laude from University of California Los Angeles, her M.D. from Harvard Medical School, and her Ph.D. from Harvard University in Experimental Pathology/Immunology.

Biography

Dr. Girardi is the endowed Evans Professor and Vice Chair of Faculty Development & Scientific Innovation for the Department of Dermatology at the Yale School of Medicine. As a physician-scientist, Dr. Girardi’s NIH-funded research program of over 20 years has significantly advanced our understanding of cutaneous lymphoma, cutaneous immunology, and cutaneous carcinogenesis. His work, featured in journals such as Science, Nature, Nature Immunology, Nature Genetics, Nature Biomaterials, and PNAS, has resulted in hundreds of papers with over 11,300 total citations. The holder of seven biomedical patents, plus four more pending, Dr. Girardi is dedicated to translating scientific discoveries into tangible applications. His global impact is evident in leadership roles on the Research Leadership Council for Advancing Innovation in Dermatology, the United States Cutaneous Lymphoma Consortium, and the International Society of Cutaneous Lymphoma. Dr. Girardi’s influence extends beyond research to mentorship, where he has guided over 50 pre-doctoral and post-doctoral research fellows, many of whom have become academic leaders in dermatology. His mentees have received prestigious awards, and include two Howard Hughes Fellowship recipients and five Yale School of Medicine Thesis Award recipients. Dr. Girardi’s commitment to innovation and mentorship is further reflected in his active involvement with the Yale Dermatology’s Faculty Mentorship Committee where he advises junior faculty on career development and early career awards, and his role as Co-Director of the Yale Dermatology NIH physician-scientist training grant. With a diverse educational background including graduating magna cum laude from Brown University with a dual degree in Biology and Computer Science and the Honors Thesis Award along an MD from the Yale School of Medicine, and many awards such as the Yale Blavatnik Award in Innovation and induction into to the American Association of Professors and the and induction into The American Society for Clinical Investigation ASCI and AAPP, Dr. Girardi is a foremost leader in dermatological research, innovation, and mentorship.

Biography

Sandy Goss joined the Digital Health strategy team at AbbVie in 2020, focusing on the development of more objective and sensitive efficacy measures in support of Immunology pipeline development. After completing her PhD at the University of Connecticut and Post-doctoral fellowship at the University of North Carolina, Sandy joined the Abbott/Abbvie clinical pharmacology department in 2008. She supported clinical pharmacology activities for all phases of development across multiple therapeutic areas and has been an advocate for novel analysis and clinical innovation. She joined the AbbVie Development Design Center in 2017 that fostered a collaborative environment to help clinical teams optimize the design and execution of their trials. She also led the exploration of decentralized trials and home health care to decrease the patient burden and helped integrate the use of real-world data in clinical decision-making.

Biography

Natalene has a cutting-edge knowledge of the aesthetic medicine business and markets. Prior to joining Fastox, Natalene was with Galderma for almost 20 years. As global head of the neurotoxin franchise (brands Dysport, Azzalure and Alluzience), she led the development and implementation of global strategies as well as the pipeline development and life cycle management of the existing portfolio.

She previously held various business development, alliance management and marketing positions within the Galderma aesthetic portfolio (fillers and toxins) as well as in dermatology. Through Beautynovate, she is a senior advisor for various companies in the medical aesthetic field and for investment funds. She trained in business.

Biography

Dr. Iyer is a Professor of Medicine at University of Texas, MD Anderson Cancer Center Houston, TX as a Lymphoma specialist. Prof. Iyer is an internationally recognized expert in clinical trials for cancer with two FDA approvals, in lymphoma and leukemia. He graduated from Bangalore Medical College, Rajiv Gandhi University of Health Sciences with a Gold Medal in Pathology in 1994. His post-graduation includes training at AIIMS, Wayne State University and University of Miami and is an American Board of Internal Medicine (ABIM) Diplomate in Internal Medicine and Hematology.
In addition, he has a laboratory interest in aptamers, chimeric antigen receptor Therapies (CAR-Ts), and machine learning approaches to predict biomarkers from whole slide images. At the University of Texas MD Anderson, he leads the T cell lymphoma (TCL) program.
Dr.Iyer serves as the President of the Indo American Cancer Association with the goal of giving back service and care for cancer patients in India. He is the recipient of several awards including American Society of Clinical Oncology Young Investigator Award, Outstanding Physician Volunteer for the Leukemia Lymphoma Society, Virginia and Cockrell Presidential Scholar at the Houston Methodist, Who’s Who in Healthcare, America’s Top Physicians, 2007-present, HealthCare Network Excellence Award 2017 and 2022. His work has been supported by grants from American Cancer Society, Leukemia Lymphoma Society, National Institute of Health and several industry partners.

Biography

Eleanor is Founder & CEO of Skintelligent, which is powering the future of intelligent skin health by developing AI-enabled precision skin imaging software solutions for dermatology & medical aesthetics. Skintelligent technology is used for both patient acquisition, as well as driving growth & experience within clinic. In her previous corporate experience, she had a global career living and working in 4 countries while in senior roles at The Coca-Cola Company in strategy, commercial & digital, across Asia Pacific. This included building up a New Ventures org for Coca-Cola China. She is a regular guest contributor to BBC program Business Matters. She holds a BA from University of North Carolina at Chapel Hill, and MBA from Emory University.

Biography

Dr. Kim received his MD from the University of Washington, was a HHMI-NIH Scholar, completed residency in dermatology at the University of Pennsylvania where he earned a Master of Translational Research (MTR). His research focuses on mechanisms that underlie skin inflammation and the sensation of itch as a fundamental, broad, model paradigm of neuroimmunology. He has >120 peer-reviewed publications, multiple NIH grants, designed pivotal clinical trials that led to novel FDA-approved treatments, and is an inventor of itch-centered technologies. His research has led to awards and funding from NIH, Doris Duke Charitable Foundation, American Skin Association, American Academy of Dermatology, American Society for Clinical Investigation, American Dermatological Association, and International League of Dermatological Societies. He holds a patent for the use of JAK inhibitors for itch. He is on the SAB for Abrax Japan, Granular Therapeutics, Recens Medical, National Eczema Association, and Cell Reports Medicine.

Biography

Dr. Kim is a Professor of Dermatology/Nutrition/Medicine at the David Geffen School of Medicine and the Director of Micrographic Surgery and Dermatologic Oncology Fellowship and Cosmetic Dermatology at UCLA. She has been a UCLA faculty member since 2000 and provides care for patients with skin cancers, aging and other appearance related conditions. Her practice is focused on a holistic and preventive care for skin health.

Dr. Kim is a physician-scientist and her lab focuses on the investigation of skin as an immune organ, studying both the innate and adaptive immune responses in dermatologic diseases, including aging and longevity, skin cancers, hair and pilosebaceous disorders. Her lab has been supported by the NIH, DF, an industry for over 20 years. She is a consultant to biotech companies, is a holder of multiple patents, and has out-licensed technology developed in her lab to several companies. Dr. Kim is the co-founder of KoreAx, a device company that focuses on aesthetics of skin, with Arch Venture Partners. She is also the co-founder of Faith in Flower, a plant based botanical brand.

Dr. Kim is passionate about her philanthropic work, having co-founded Camp Wonder in 2001, a camp that serves children with severe skin disorders. She has been on the board of the Women’s Dermatologic Society, leader of EDI at UCLA School of Medicine, and a member of the Museum of Contemporary Art emerging artist committee.

Biography

Dr. Ko is Chief of Medical Dermatology at Stanford and spearheads the dermatology department’s efforts around digital health, quality and value-based care. He is active in a number of leadership roles within Stanford Medicine including as an Associate Chief Quality Officer and physician lead of Patient Experience. His passion for innovating on models of care delivery drives his clinical and research efforts around layering advances in artificial intelligence on remote care capabilities to enhance access, quality and value of dermatologic care.

Biography

Dr. Leachman is a physician-scientist who chairs the Department of Dermatology at Oregon Health & Science University (OHSU) and is the director of the Melanoma Research Program at the OHSU Knight Cancer Institute, an NCI-designated Comprehensive Cancer Center. She is a dermatologist using basic science research and state-of-the-art technology to combat skin cancer. Her clinical interests include skin cancers, especially melanoma, pigmentary disorders that result from abnormalities of melanocytes such as vitiligo, and genetic disorders that involve the skin such as pachyonychia congenita, Cowden syndrome, and other cutaneous cancer syndromes. Dr. Leachman’s research interest is in the prevention, early detection and chemoprevention of melanoma. She is currently fighting the “War on Melanoma” in Oregon and developed Mole Mapper, a mobile phone app to facilitate early detection. Leachman is currently performing a statewide experiment in Oregon called “Start Seeing Melanoma” designed to determine whether education about melanoma early detection will decrease mortality and cost of the disease.

Biography

Dr. Luke is a Supervisory Physician and Director of the Division of Therapeutic Performance (DTP1) in the Office of Research and Standards, Office of Generic Drugs at FDA. DTP1 is responsible for facilitating pre-application development of generic drugs by conducting and promoting regulatory science research to establish standards to ensure therapeutic equivalence of new generic drug products. Markham has an MD and a PhD in Pharmacology from Johns Hopkins University and is a dermatologist by training. Markham has research interests in dermatopharmacology, clinical pharmacology, clinical study design and endpoints assessment (including patient-reported outcomes) for medical, surgical, and aesthetic products and serves as consultant dermatologist to various parts of FDA. Markham has been at FDA since 1998 serving various roles, including as the Lead Medical Officer for dermatology drugs, Chief Medical Officer and Deputy Director for the Office of Device Evaluation in the Center for Devices and Radiologic Health, and as Acting Director for Cosmetics in the Center for Food Safety and Applied Nutrition. In each of these roles including his current one, Markham has been involved in programs and initiatives dealing with product innovation as related to Public Health for our nation.

Biography

Alfonso Medela is a co-founder and Chief AI Officer at Legit.Health, a startup that has revolutionized the dermatology field through advanced artificial intelligence algorithms. With a background in physics, his career has centered on applying computer vision to medical imaging, emphasizing the practical use of these algorithms in clinical settings. His robust scientific expertise includes notable publications in few-shot learning and dermatology, and he has actively participated in numerous dermatology congresses, sharing the latest breakthroughs achieved at Legit.Health.

Biography

Dr. Nalamothu is the Founder, Executive Chairman & CSO of Tergus Pharma, a North Carolina-based CDMO which specializes in complete topical drug product development services, skin permeation, in vitro testing, and commercial GMP manufacturing. Dr. Nalamothu earned his Ph.D. in Pharmaceutics from the University of the Science’s Philadelphia College of Pharmacy. His efforts over the past 26 years in various dermatological companies have led to many commercial products in the market today. He has successfully taken Tergus Pharma from a small R&D facility to a 100,000 SFT commercial manufacturing facility with industry-leading capacities. His knowledge of the unmet needs in the Dermatology CDMO industry led to equipping Tergus Pharma with unique R&D capabilities such as Skin Biology and In Vitro Permeation (IVRT & IVPT) as well as Hormone and High Potent compound manufacturing at a commercial scale. Dr. Nalamothu draws from his exceptional background that combines scientific study with pragmatic, hands-on experience to solve R&D challenges and his ability to translate a concept into a commercial product. He has co/authored numerous publications and has patents for a few of his inventions. He serves as a member of various pharmaceutical associations as well as sits on the boards of various pharmaceutical companies. In his spare time, Dr. Nalamothu enjoys his quiet time with family and boating on Raleigh’s Falls Lake.

Biography

Dr. Nghiem leads a multidisciplinary team focused on improving the management of a highly aggressive, polyomavirus-driven skin cancer, Merkel cell carcinoma. Studies led by his team have resulted in several impactful developments in the management of MCC. These include all three FDA-approved therapies for MCC, the only NCCN-recommended blood test to assess if the cancer is recurring, the AJCC staging system used internationally to determine MCC prognosis, and over a dozen clinical trials in various stages of completion. He will discuss the impact of these innovations and how they required creative collaborations with patient groups, organizations that collect national cancer data, Biotech, Pharma, philanthropy, and carefully leveraging limited NIH funding.

Biography

Dr. Papier is a founder of VisualDx and CEO. A dermatologist, Art has a particular interest for excellence in interface design and usability. In line with this passion, he has led the development of VisualDx, an electronic record integrated decision tool and mobile app that incorporates machine learning for skin rashes and lesions. Art is also passionate about the engagement of people in their medical decisions, in consumer health, and developing tools to educate and empower patients in their homes and on their mobile devices. The focus of his work is to assist medical decisions by professionals and people alike, with decision support and AI augmenting human intelligence.

A graduate of Wesleyan University, Art received his MD from the University of Vermont College of Medicine and completed his graduate medical training at the University of Rochester Medical Center. He is also an Associate Professor of Dermatology and Medical Informatics at the University of Rochester School of Medicine and Dentistry.

Biography

Ajay Nair Sharma, MD, MBA, is a current dermatology resident at the University of California, Irvine. As a PGY-3, Ajay has already demonstrated a fierce commitment to leadership within his field, applying his business school background in healthcare management and policy to provide a data-driven approach to some of the most pressing issues within dermatology. Ajay’s research has focused on cutaneous oncologic treatment, predictive analytics for outcomes, and quality improvement in medicine, with over 40 peer-reviewed publications and counting. His experience as Student Body President of his medical school similarly exposed him to the myriad challenges faced by his peers in training. To this end, Ajay co-founded Diary of a Med Student, a best-selling book turned non-profit organization that captured stories from medical students across the world. Today he is the recipient of several awards and an elected member of the Alpha Omega Alpha Honor Medical Society and the Gold Humanism Honor Society. In his free time, Ajay enjoys working as a talented medical artist, playing soccer, and public speaking.

Biography

Dr. Emma Taylor is Chief Medical Officer at DermBiont. She is a UCLA-trained board-certified dermatologist and dermatopathologist, having served as faculty at UCLA, published in high-impact journals (Nature, JAAD, etc.), and contributed as an inventor on multiple issued patents. Prior to joining DermBiont, Dr. Taylor was founder and CEO at Naked Biome, where she successfully advanced the company’s lead product through phase one clinical trials for acne and led the company through acquisition.

Biography

Dr. Sauvageau, originally from Buffalo, NY, pursued his medical education at the University of Buffalo, where he obtained his medical degree. He furthered his specialization in dermatology by completing his residency at the University of Michigan. Driven by a passion for advancing patient care and medical knowledge, he is currently immersed in a fellowship program at UCLA, specializing in Mohs Micrographic Surgery and Cutaneous Oncology. Within this role, Andrew is actively engaged in research aimed at improving patient outcomes in Mohs surgery and investigating innovative approaches to address skin aging and promote longevity. His commitment to excellence in both clinical practice and research underscores his dedication to advancing the field of dermatology.

Biography

Dr. H. Tom Soh is a Professor of Electrical Engineering and Radiology at Stanford University. He earned his B.S. with a double major in Mechanical Engineering and Materials Science with Distinction from Cornell University and Ph.D. in Electrical Engineering from Stanford University. Between 1999 and 2003, he served as a technical manager of MEMS device research group at Bell Laboratories and Agere Systems. Between 2003 and 2015, he was the Ruth Garland Professor at UC-Santa Barbara (UCSB) in the department of Mechanical Engineering and Materials. His lab moved to Stanford in 2015. He is a recipient of numerous awards including MIT Technology Review’s “TR 100” Award, ONR Young Investigator Award, Beckman Young Investigator Award, ALA Innovator Award, NIH TR01 Award, Guggenheim Fellowship, Humboldt Fellowship, and was a Chan-Zuckerberg Biohub Investigator. He is a fellow of the American Institute for Medical and Biological Engineering (AIMBE) and member of the National Academy of Inventors (NAI).

Biography

Dr. Xu is currently the CEO and cofounder of Sibel Health – an award winning digital health company spun out of his research and the Querrey Simpson Institute for Bioelectronics of Northwestern University. He also holds the position as the Ruth K. Freinkel MD Professor at Northwestern University and Medical Director of the Querrey Simpson Institute for Bioelectronics at Northwestern University. He received his undergraduate degree in bioengineering from Rice University summa cum laude. He completed his medical training at Harvard Medical School with special honors as a Soros Fellow, and a Masters in Health Policy and Finance with Merit from The London School of Economics as a Marshall Scholar. Dr. Xu has authored more than 130 peer-reviewed publications and listed as an inventor on 15 pending and granted patents. His work has been funded from the NIH, DoD, FDA, and the Bill & Melinda Gates Foundation. He has developed numerous digital health technologies applied broadly across numerous clinical indications. His publications have appeared in The New England Journal of Medicine, Science, Nature, and The Proceedings of the National Academy of Sciences, garnering press attention from sources such as The New York Times, The Wall Street Journal, and The Washington Post. His technologies have garnered four FDA-clearances, and launched in 20 countries across 6 continents.

Biography

Frederick C. Beddingfield III is a physician-scientist and biotech entrepreneur. He is currently an Executive Partner at Apollo Health Ventures. Previously Frederick was the CEO and member of the board of directors of Kira Pharmaceuticals, a development stage complement therapeutics biotech company focused on immunology, inflammation, and rare diseases. He was founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. and took the company public in 2017. Prior to Sienna, Frederick served as Chief Medical Officer of Kythera Biopharmaceuticals from March 2013 until it was acquired by Allergan in 2015. Frederick worked at Allergan for 10 years (2003-2013) where he served in various roles including the Therapeutic Area Head of Dermatology and Chief Medical Officer Allergan Medical. He has led the development and approvals of global leading brands in medical dermatology, aesthetics, neurology, metabolic, and other therapeutic areas. These brands include Botox (cosmetic, hyperhidrosis, spasticity, and other), Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac. Frederick has led four successful FDA advisor committees.

Since completing his training, Frederick has maintained a clinical and teaching practice at UCLA. He is a board-certified dermatologist and emergency medicine physician and fellowship trained in dermatologic surgery and cutaneous oncology. Frederick completed his medical degree with honors at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the board of directors of Cytrellis Biosystems, Inc. and on the medical advisory board of the Children’s Skin Disease Foundation and Camp Wonder. He is on the board and co-founder of the Dermatology Summit and Dermatology Innovation Forum conferences, part of Advancing Innovation in Dermatology, a non-profit organization.

Biography

William Ju, MD, FAAD is a board-certified dermatologist and has over 20 years of biopharmaceutical experience in a wide variety of therapeutic areas, including dermatology. He is president and a co-founding trustee of Advancing Innovation in Dermatology, Inc. Dr. Ju has been president and chief executive officer of Follica, Inc. and chief operating officer at PTC Therapeutics, Inc. (PTCT). In addition, he has held executive positions at Pharmacia Corporation/Pfizer, Inc. Merck & Co., Inc., and Hoffmann La Roche, Inc. in a broad range of product development and leadership functions. Dr. Ju served as project leader for SUTENT®, introduced CANCIDAS® into humans, and was part of the product development teams for CRIXIVAN® and TRANSLARNA™.

Dr. Ju began his pharmaceutical career at Hoffmann-La Roche where he was a clinical leader for the development of dermatology compounds. Before entering industry, Dr. Ju was a senior staff fellow in basic research in the Laboratory of Cellular Oncology under Douglas Lowy, M.D. and was affiliated with the Dermatology Branch at the National Cancer Institute, National Institutes of Health. He obtained his M.D. with Alpha Omega Alpha honors at the University of Pennsylvania School of Medicine and his A.B. with Phi Beta Kappa honors at Princeton University.

Biography

Seth Orlow, MD, PhD has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale.

Biography

Dr. Slaoui has served as Chief Corporate Development Officer at Galderma since September 2020. Previously she spent 20 years with GSK, first in the research labs, where her work in pulmonary disease resulted in the discovery of the long acting muscarinic receptor antagonist in the approved medicines Anoro™ Ellipta™, Incruse™ Ellipta™, and Trelegy™ Ellipta™. She holds multiple patents, has authored more than 40 original peer-reviewed publications, and she has had ongoing roles as a peer reviewer for a dozen established medical journals. Since joining GSK’s Business Development teams in 2006, she has held various roles of increasing seniority and has executed more than $30 billion worth of deals and acquisitions, including the $3.6 billion acquisition of Stiefel Laboratories in 2009, participating in the $20+ billion three-part transaction with Novartis in 2015, and the $5.1 bn acquisition of Tesaro in 2018, with transactions covering the pharma R&D, commercial, emerging markets, specialty pharma and consumer spaces.

Dr. Slaoui earned Bachelor’s degrees in both Biology and Classical Studies from Gettysburg College. She earned her Ph.D. in Physiology from The Johns Hopkins Bloomberg School of Public Health, and completed an NIH Post-Doctoral Fellowship in Pharmacology at the University of Washington in Seattle, WA. After her term in Seattle, she accepted a position in Respiratory Drug Discovery at GSK, but continued her commitment to academic research by spending over a decade as an adjunct assistant professor at her alma mater, The Johns Hopkins Bloomberg School of Public Health in Baltimore, MD.

Biography

Qing Yu Christina Weng is a physician-scientist, entrepreneur, and biotech executive. She is the Chief Medical Officer of Pelage Pharmaceuticals, a biotech company developing innovative treatments for hair loss by targeting stem cell metabolism. Prior to Pelage, Christina was the Head of Business Development & Strategy and Senior Medical Director of Kira Pharmaceuticals, a global company developing complement therapeutics. Christina co-founded Mymiel, a high-performance clean skincare line, where she served as Chief Strategy Officer. As faculty at Harvard Medical School and attending dermatologist at the Massachusetts General Hospital (MGH), she specializes in melanoma and pigmentary disorders.

Christina attended the California Institute of Technology, where she received her bachelor’s degrees in Biology and English with honors. She graduated Magna Cum Laude from Harvard Medical School, where she received her medical degree and was a medical fellow of the Howard Hughes Medical Institute. She completed dermatology residency at the Harvard Combined Dermatology Residency Training Program with advanced clinical training at the MGH Laser & Cosmetics Center. Her postdoctoral research was at the Cutaneous Biology Research Center of MGH.

Christina’s bench research has focused on melanocyte biology and mechanisms leading to pigment dysregulation, with an emphasis on clinically translatable opportunities in pigmentary disorders and melanoma. Christina’s clinical research has led to new guidelines recommended by the American Academy of Dermatology for drug monitoring. She has received research support and awards from the Howard Hughes Medical Institute, American Skin Association, American Dermatological Association, and National Institutes of Health.